π¬Deep Research
IDXX β IDEXX Laboratories Β· catalysts, narrative & risks
IDEXX Laboratories (IDXX) β Research Snapshot as of 2026-10-03
Listing / classification: NASDAQ (S&P 500 member), filed under animal_health. [22][23][24]
Key Recent Catalysts (JulyβOctober 2026)
1. Q2 2026 earnings beat (reported August 4, 2026). IDEXX reported diluted EPS of $4.27 (up ~18% year-over-year, beating the Zacks Consensus estimate by ~8.1%) and revenue of $1.22 billion (up ~10%), exceeding consensus on both lines. Companion Animal Group (CAG) Diagnostics recurring revenues rose 11% as reported / 10% organically. [10][18][23][24]
AI-assisted research from the K3vl4r desk β not personalized investment advice. More research β